



Cite this: *RSC Adv.*, 2021, 11, 20003

## Correction: Characterization of an exopolysaccharide from probiont *Enterobacter faecalis* MSI12 and its effect on the disruption of *Candida albicans* biofilm

G. Seghal Kiran,<sup>a</sup> S. Priyadharshini,<sup>a</sup> K. Anitha,<sup>a</sup> Elumalai Gnanamani<sup>b</sup> and Joseph Selvin<sup>\*c</sup>

DOI: 10.1039/d1ra90123k

rsc.li/rsc-advances

Correction for 'Characterization of an exopolysaccharide from probiont *Enterobacter faecalis* MSI12 and its effect on the disruption of *Candida albicans* biofilm' by G. Seghal Kiran et al., *RSC Adv.*, 2015, 5, 71573–71585, DOI: 10.1039/C5RA10302A.

The authors regret that incorrect versions of Fig. 7 and 8 were included in the original article. The correct versions of Fig. 7 and 8 are presented below with updated captions.


Accordingly, the experimental methods followed in the phase contrast microscopy and large-size images of Fig. 7 have been provided in the ESI. The ESI has been updated online to reflect this change.

<sup>a</sup>Department of Food Science and Technology, Pondicherry University, Puducherry – 605014, India. E-mail: seghalkiran@gmail.com

<sup>b</sup>Department of Chemistry, Stanford University, Stanford, USA. E-mail: gnanam@stanford.edu


<sup>c</sup>Department of Microbiology, School of Life Sciences, Pondicherry University, Puducherry – 605014, India. E-mail: josephselvinss@gmail.com; jselvin.mib@pondiuni.edu.in; Fax: +91-413-2655358; Tel: +91-413-2655358





**Fig. 7** Phase contrast micrographs showing biofilm disruption potential of MSI12-EPS on *C. albicans*. The *C. albicans* biofilm was developed on a cover glass and then it was treated with varying concentrations of EPS and fluconazole ranging from 50–250  $\mu\text{g}$ . The treated cover glass was stained with crystal violet and observed under a phase-contrast microscope (Nikon) at  $\times 40$  magnification. A – Control biofilm, B1 – 50 mg fluconazole, B2 – 50  $\mu\text{g}$  MSI12-EPS, C1 – 100 mg fluconazole, C2 – 100  $\mu\text{g}$  MSI12-EPS, D1 – 150 mg fluconazole, D2 – 150  $\mu\text{g}$  MSI12-EPS, E1 – 200 mg fluconazole, E2 – 200  $\mu\text{g}$  MSI12-EPS and F1 – 250 mg fluconazole, F2 – 250  $\mu\text{g}$  MSI12-EPS. The images were recorded using a uniform scale of 10  $\mu\text{m}$  which is shown in the image panels.





**Fig. 8** Confocal laser scanning micrographs showing biofilm disruption potential of MSI12-EPS on *C. albicans*. The pre-formed biofilm was treated for 24 h with EPS and fluconazole of varying concentrations ranging from 50–250  $\mu\text{g}$ . Untreated biofilms were used as controls and the biofilm coverage thus formed on glass slides were stained with 0.1% acridine orange and subjected to visualization in a CLSM (LSM 710, Carl Zeiss). A – Control biofilm, B1 – 50 mg fluconazole, B2 – 50  $\mu\text{g}$  MSI12-EPS, C1 – 100 mg fluconazole, C2 – 100  $\mu\text{g}$  MSI12-EPS, D1 – 150 mg fluconazole, D2 – 150  $\mu\text{g}$  MSI12-EPS, E1 – 200 mg fluconazole, E2 – 200  $\mu\text{g}$  MSI12-EPS and F1 – 250 mg fluconazole, F2 – 250  $\mu\text{g}$  MSI12-EPS.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

